These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38233072)

  • 1. Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis.
    Wuttiputhanun T; Naiyarakseree N; Udomkarnjananun S; Kittanamongkolchai W; Asada L; Chariyavilaskul P; Townamchai N; Avihingsanon Y
    Lupus Sci Med; 2024 Jan; 11(1):. PubMed ID: 38233072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Br J Clin Pharmacol; 2015 Nov; 80(5):1064-75. PubMed ID: 25959850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
    Łuszczyńska P; Pawiński T
    Ther Drug Monit; 2015 Dec; 37(6):711-7. PubMed ID: 26034895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
    Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To TDM or not to TDM in lupus nephritis patients treated with MMF?
    van Gelder T; Berden JH; Berger SP
    Nephrol Dial Transplant; 2015 Apr; 30(4):560-4. PubMed ID: 24811231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S; Fleming DH; Mathew BS; Varughese S; Jeyaseelan V; Tamilarasi V; Jacob CK; John GT
    Ther Drug Monit; 2014 Aug; 36(4):423-32. PubMed ID: 25014074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of trough mycophenolic acid levels for the management of lupus nephritis.
    Pourafshar N; Karimi A; Wen X; Sobel E; Pourafshar S; Agrawal N; Segal E; Mohandas R; Segal MS
    Nephrol Dial Transplant; 2019 Jan; 34(1):83-89. PubMed ID: 29548021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis.
    Romano-Aguilar M; Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Martínez-Martínez MU; Abud-Mendoza C; Romano-Moreno S
    Lupus; 2020 Aug; 29(9):1067-1077. PubMed ID: 32539658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients.
    Punyawudho B; Lertdumrongluk P; Somparn P; Kittanamongkolchai W; Traitanon O; Avihingsanon Y; Vadcharavivad S
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):272-80. PubMed ID: 22456298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
    Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
    Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.